Jaguar Health Special Meeting Fails to Reach Quorum; No Vote on Dilutive Proposals
JAGX is trading near its 52-week low of $0.572 (6.4% below the low) on elevated volume (15× avg).
Summary
Jaguar Health's special meeting on September 4, 2026, lacked a quorum, so no vote was taken on the proposed dilutive financing actions. The company will not reconvene the meeting and will evaluate whether to call a new one.
Key Events · Corporate Governance and Compliance · JAGX
-
Special Meeting Lacks Quorum
The September 4, 2026 special meeting was called to order but did not have enough shares present or represented by proxy to constitute a quorum, so no vote was taken on any proposal.
-
No Reconvening Planned
The company will not adjourn or postpone the meeting to solicit additional proxies; the meeting will not be reconvened.
-
Future Meeting Under Evaluation
Jaguar Health will evaluate whether to call a new special meeting in the future to consider the same or similar proposals.
-
Financing Proposals in Limbo
The three highly dilutive actions sought in the proxy remain unapproved, adding uncertainty to the company's capital-raising efforts amid a going concern warning and $3.8M cash balance.
Analysis · JAGX · Life Sciences
The special meeting called to approve three highly dilutive financing actions failed to achieve quorum, so no vote occurred. The company will not reconvene the meeting, leaving the fate of those proposals uncertain. This is a material setback for the company's financing plans, which were already under pressure from a going concern warning and limited cash.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 29.9% of the 1988 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.12%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, JAGX was trading at $0.54 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.1M. The 52-week trading range was $0.57 to $85.40. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.